Chiome Bioscience Inc. (4583.T)
JPY 130.0
(1.54%)
JPY 130.0
(1.54%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 1.75 Billion JPY | -20.94% |
| 2022 | 2.21 Billion JPY | -5.3% |
| 2021 | 2.33 Billion JPY | -33.05% |
| 2020 | 3.49 Billion JPY | 24.45% |
| 2019 | 2.8 Billion JPY | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 1.55 Billion JPY | -11.2% |
| 2024 Q1 | 1.75 Billion JPY | 0.14% |
| 2023 FY | 1.75 Billion JPY | -20.94% |
| 2023 Q2 | 1.68 Billion JPY | -19.18% |
| 2023 Q1 | 2.08 Billion JPY | -5.86% |
| 2023 Q3 | 1.75 Billion JPY | 4.01% |
| 2023 Q4 | 1.75 Billion JPY | -0.1% |
| 2022 Q3 | 2.08 Billion JPY | 0.0% |
| 2022 Q4 | 2.21 Billion JPY | 6.44% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 6.58 Billion JPY | 73.42% |
| PRISM BioLab Co.,LTD | 1.21 Billion JPY | -44.578% |
| GNI Group Ltd. | 62.39 Billion JPY | 97.193% |
| Linical Co., Ltd. | 18.53 Billion JPY | 90.553% |
| Trans Genic Inc. | 9.81 Billion JPY | 82.148% |
| MEDINET Co., Ltd. | 5.63 Billion JPY | 68.914% |
| Soiken Holdings Inc. | 6.94 Billion JPY | 74.785% |
| Cytori Cell Research Institute, Inc. | 5.81 Billion JPY | 69.887% |
| AnGes, Inc. | 28.89 Billion JPY | 93.938% |
| OncoTherapy Science, Inc. | 867.27 Million JPY | -101.949% |
| Nxera Pharma Co., Ltd. | 157.19 Billion JPY | 98.886% |
| Immuno-Biological Laboratories Co., Ltd. | 1.61 Billion JPY | -8.209% |
| NanoCarrier Co., Ltd. | 5.07 Billion JPY | 65.463% |
| Carna Biosciences, Inc. | 4.34 Billion JPY | 59.736% |
| CanBas Co., Ltd. | 2.43 Billion JPY | 28.008% |
| D. Western Therapeutics Institute, Inc. | 2.37 Billion JPY | 26.204% |
| RaQualia Pharma Inc. | 6.93 Billion JPY | 74.727% |
| Kidswell Bio Corporation | 5.08 Billion JPY | 65.56% |
| PeptiDream Inc. | 67.12 Billion JPY | 97.391% |
| Oncolys BioPharma Inc. | 2.04 Billion JPY | 14.17% |
| Ribomic Inc. | 3.54 Billion JPY | 50.625% |
| SanBio Company Limited | 5.04 Billion JPY | 65.299% |
| Healios K.K. | 15.15 Billion JPY | 88.443% |
| BrightPath Biotherapeutics Co., Ltd. | 1.23 Billion JPY | -42.365% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 3.01 Billion JPY | 41.928% |
| Delta-Fly Pharma, Inc. | 1.47 Billion JPY | -18.811% |
| StemRIM | 9.08 Billion JPY | 80.711% |
| CellSource Co., Ltd. | 6.87 Billion JPY | 74.542% |
| FunPep Company Limited | 2.49 Billion JPY | 29.693% |
| Kringle Pharma, Inc. | 2.61 Billion JPY | 33.116% |
| Stella Pharma Corporation | 3.82 Billion JPY | 54.158% |
| TMS Co., Ltd. | 3.55 Billion JPY | 50.729% |
| Noile-Immune Biotech Inc. | 5.77 Billion JPY | 69.693% |
| Cuorips Inc. | 6.18 Billion JPY | 71.681% |
| K Pharma,Inc. | 3.31 Billion JPY | 47.148% |
| Takara Bio Inc. | 123.2 Billion JPY | 98.578% |
| ReproCELL Incorporated | 9.05 Billion JPY | 80.653% |
| PhoenixBio Co., Ltd. | 2.71 Billion JPY | 35.497% |
| StemCell Institute Inc. | 6.54 Billion JPY | 73.232% |
| Japan Tissue Engineering Co., Ltd. | 6.98 Billion JPY | 74.939% |
| CellSeed Inc. | 2.46 Billion JPY | 28.969% |